Targetable genetic features of primary testicular and primary central nervous system lymphomas

Blood

Volumn 127, Issue 7, 2016, Pages 869-881

  Chapuy, Bjoern ^a   Roemer, Margaretha G M ^a,b   Stewart, Chip ^c   Tan, Yuxiang ^d   Abo, Ryan P ^a   Zhang, Liye ^d   Dunford, Andrew J ^c   Meredith, David M ^e   Thorner, Aaron R ^a   Jordanova, Ekaterina S ^f   Liu, Gang ^d   Feuerhake, Friedrich ^g   Ducar, Matthew D ^a   Illerhaus, Gerald ^h   Gusenleitner, Daniel ^d   Linden, Erica A ⁱ   Sun, Heather H ^e   Homer, Heather ^a   Aono, Miyuki ^a   Pinkus, Geraldine S ^e   Ligon, Azra H ^e   Ligon, Keith L ^e   Ferry, Judith A ⁱ   Freeman, Gordon J ^a   Van Hummelen, Paul ^a   Golub, Todd R ^a,c   Getz, Gad ^c,i   Rodig, Scott J ^e   De Jong, Daphne ^b   Monti, Stefano ^d   Shipp, Margaret A ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Center for Gynaecologic Oncology   (Netherlands)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN P53; TOLL LIKE RECEPTOR; TUMOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; IMMUNE EVASION; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIMARY TESTICULAR LYMPHOMA; PRIORITY JOURNAL; SOMATIC MUTATION; CENTRAL NERVOUS SYSTEM TUMOR; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; GENE LOCUS; GENE TRANSLOCATION; GENETICS; MALE; MEDIASTINUM TUMOR; METABOLISM; PATHOLOGY; TESTIS TUMOR;

CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GENETIC LOCI; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; NEOPLASM PROTEINS; TESTICULAR NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84959419747     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-673236     Document Type: Article

References (71)

1. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013;122(14):2318-2330.
2. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4): 486-493.
3. Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med. 2011;135(10):1363-1367.
4. Deckert M, Montesinos-Rongen M, Brunn A, Siebert R. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol. 2014;127(2):175-188.
5. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immuneprivileged sites. Blood. 2000;96(10):3569-3577.
6. Deng L, Xu-Monette ZY, Loghavi S, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2013; 10.1038/leu.2015.237 [Epub ahead of print].
7. Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015; 15(3):172-184.
8. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
9. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
10. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-1679.
11. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5): 1851-1861.
12. Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22(4):547-560.
13. Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKTdependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826-838.
14. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3):359-372.
15. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659-2669.
16. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
17. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
18. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011; 471(7338):377-381.
19. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13): 2062-2065.
20. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-264.
21. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
22. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015;372(4):311-319.
23. Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203-5211.
24. Braggio E, McPhail ER, MaCon W, et al. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011;17(13): 4245-4253.
25. Booman M, Szuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol. 2008;216(2):209-217.
26. Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014;5(13): 5065-5075.
27. Vater I, Montesinos-Rongen M, Schlesner M, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015;29(3): 677-685.
28. Braggio E, Van Wier S, Ojha J, et al. Genomewide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986-3994.
29. Kraan W, van Keimpema M, Horlings HM, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28(3):719-720.
30. Oishi N, Kondo T, Nakazawa T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. Pathol Int. 2015;65(10):528-535.
31. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007;104(50):20007-20012.
32. Nogai H, Wenzel SS, Hailfinger S, et al. IkB-z controls the constitutive NF-kB target gene network and survival of ABC DLBCL. Blood. 2013; 122(13):2242-2250.
33. Yamamoto M, Yamazaki S, Uematsu S, et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004;430(6996):218-222.
34. Krappmann D. Shaping oncogenic NF-kB activity in the nucleus. Blood. 2013;122(13):2146-2147.
35. Hernando E, Nahle Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430(7001):797-802.
36. Wang L, He G, Zhang P, Wang X, Jiang M, Yu L. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Mol Biol Rep. 2011;38(1):229-236.
37. Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53- dependent mechanism. J Cell Biol. 2010;188(3): 369-381.
38. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-166.
39. Shlien A, Tabori U, Marshall CR, et al. Excessive genomic DNA copy number variation in the Li- Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA. 2008;105(32):11264-11269.
40. Karras JR, Paisie CA, Huebner K. Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis. Cancers (Basel). 2014;6(2): 1208-1219.
41. Drier Y, Lawrence MS, Carter SL, et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013;23(2):228-235.
42. Abo RP, Ducar M, Garcia EP, et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015;43(3):e19.
43. Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancerassociated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777-790.
44. Schneider C, Setty M, Holmes AB, et al. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci USA. 2014;111(22):8185-8190.
45. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945-961.
46. Boyd RS, Adam PJ, Patel S, et al. Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B. Leukemia. 2003; 17(8):1605-1612.
47. Park HY, Go H, Song HR, et al. Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. J Clin Invest. 2014; 124(11):4976-4988.
48. Tan Y, Chapuy B, Shipp M, Monti S. FusionQuery: a novel tool for gene-specific fusion detection. International Conference on Intelligent Systems for Molecular Biology (ISMB), July 11-15, 2014, N06.
49. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218.
50. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev. 2012;247(1):73-92.
51. Tijchon E, Havinga J, van Leeuwen FN, Scheijen B. B-lineage transcription factors and cooperating gene lesions required for leukemia development. Leukemia. 2013;27(3):541-552.
52. Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR derepression checkpoint. Mol Cell. 2009;35(1):48-57.
53. Gil J, Peters G. Regulation of the INK4b-ARFINK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006;7(9):667-677.
54. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879-3884.
55. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(4):1398-1403.
56. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
57. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
58. Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122(7):1256-1265.
59. Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol. 2013;14(10): 1084-1092.
60. Jabara HH, McDonald DR, Janssen E, et al. DOCK8 functions as an adaptor that links TLRMyD88 signaling to B cell activation. Nat Immunol. 2012;13(6):612-620.
61. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012;12(4):282-294.
62. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611-1618.
63. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virusassociated malignancies. Clin Cancer Res. 2013; 19(13):3462-3473.
64. Chang YS, Graves B, Guerlavais V, et al. Stapled a-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci USA. 2013; 110(36):E3445-E3454.
65. Wang JQ, Jeelall YS, Beutler B, Horikawa K, Goodnow CC. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J Exp Med. 2014;211(3):413-426.
66. Yang Y, Shaffer AL III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6): 723-737.
67. Jeelall YS, Wang JQ, Law HD, et al. Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. J Exp Med. 2012;209(11):1907-1917.
68. Thurner L, Kemele M, Fadle N, et al. Postranslationally modified proteins in the central nervous system (CNS) are the dominant antigenic target/stimulus of the B-cell receptor (BCR) in primary CNS lymphomas (PCNSL) providing strong evidence for the role of chronic autoantigenic stimulation as an early step in the pathogenesis of aggressive B-cell lymphomas [abstract]. Blood. 2014;124(21). Abstract 142.
69. Trepel M, Muller F, Illerhaus G, Glatzel M, Binder M, Spies E. B-cell receptors of primary central nervous system lymphoma recognize antigens in the brain [abstract]. Blood. 2014; 124(21). Abstract 3003.
70. Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA. 2015;112(10): E1116-E1125.
71. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.